Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin Combined With Capecitabine for Adjuvant Treatment in Estrogen Receptor Positive, Early-Stage Breast Cancer

摘要

Eribulin plus capecitabine as adjuvant therapy was feasible in postmenopausal women with early-stage, human epidermal growth factor receptor 2-negative, estrogen receptor-positive breast cancer. The mean relative dose intensity was 90.6%, and the feasibility rate was 81.3% with the standard dosing schedule for both drugs. An alternative schedule for capecitabine (7 days on, 7 days off) was better tolerated in a supplemental group of 10 patients.